Jianfeng Zhou

Dr. Jianfeng Zhou


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
PFPinhao Fang
Pinhao Fang
JZJianfeng Zhou
Jianfeng Zhou
YLYixin Liu
Yixin Liu
ZLZhiwen Liang
Zhiwen Liang
YYYushang Yang
Yushang Yang
YYYong Yuan
Yong Yuan
Background: Currently, mediastinoscopy-assisted esophagectomy (MAE) and thoracoscope-assisted esophagectomy (TAE) represent two prevalent forms of minimally invasive esophagectomy extensively employed in the management of esophageal cancer (EC). The aim of this meta-analysis is to assess and compare these two surgical approaches concerning perioperative outcomes and long-term survival, offering valuable insights for refining surgical strategies and enhancing patient outcomes in this field. Methods: Adhering to PRISMA guidelines, the authors systematically searched PubMed, Web of Science, Cochrane Library, Embase, and CNKI databases until 1 March 2024, for studies comparing MAE and TAE. Outcomes of interest included perioperative outcomes (intraoperative outcomes, postoperative recovery, postoperative complications) and survival rates. Statistical analyses were performed using RevMan 5.4, with heterogeneity dictating the use of fixed or random-effects models. Results: A total of 21 relevant studies were finally included. MAE was associated with significantly shorter operation times [mean difference (MD)=−59.58 min, 95% CI: −82.90 to −36.26] and less intraoperative blood loss (MD=−68.34 ml, 95% CI: −130.45 to −6.23). However, MAE resulted in fewer lymph nodes being dissected (MD=−3.50, 95% CI: −6.23 to −0.78). Postoperative recovery was enhanced following MAE, as evidenced by reduced hospital stays and tube times. MAE significantly reduced pulmonary complications [odds ratio (OR)=0.59, 95% CI: 0.44, 0.81] but increased the incidence of recurrent laryngeal nerve injury (OR=1.84, 95% CI: 1.30, 2.60). No significant differences were observed in anastomotic leakage, chylothorax, cardiac complications, wound infections, and gastric retention between MAE and TAE. The long-term survival outcomes showed no statistical difference [hazard ratio (HR)=1.05, 95% CI: 0.71, 1.54]. Conclusions: MAE offers advantages in reducing operation time, blood loss, and specific postoperative complications, particularly pulmonary complications, with a shorter recovery period compared to TAE. However, it poses a higher risk of recurrent laryngeal nerve injury and results in fewer lymph nodes being dissected. No difference in long-term survival was observed, indicating that both techniques have distinct benefits and limitations. These findings underscore the need for personalized surgical approaches in EC treatment, considering individual patient characteristics and tumor specifics.

29 May 2024 in International Journal of Surgery
Verified
Journal Article
Open access
JZJianfeng Zhou
Jianfeng Zhou
YLYixin Liu
Yixin Liu
YYYushang Yang
Yushang Yang
PFPinhao Fang
Pinhao Fang
LCLong-Qi Chen
Long-Qi Chen
YYYong Yuan
Yong Yuan
An abstract is unavailable. This article is available as a PDF only.

3 July 2024 in International Journal of Surgery
Verified
Journal Article
Open access
SLSiyuan Luan
Siyuan Luan
XXXin Xiao
Xin Xiao
XZXiaoxi Zeng
Xiaoxi Zeng
JRJie Ren
Jie Ren
WLWen Liu
Wen Liu
YYYong Yuan
Yong Yuan
Background: The therapeutic strategy for patients with spontaneous rupture of the esophagus includes surgical repair, endoscopic therapy, supportive care, and others. However, no evidence exists to direct clinical decision-making regarding the choice of operative and nonoperative management. This study aimed to determine the clinical efficacy of different therapeutic strategies in both general and stratified patients. Methods: This study retrospectively analyzed a consecutive cohort of 101 patients at nine tertiary referral hospital centers in China. Patients were divided into operative and nonoperative groups based on the initial treatment. Short-term outcomes, including 90-day mortality, length of hospital stay, and postoperative leakage, were compared. Subgroup analysis was performed based on treatment timing and Pittsburgh perforation severity score. Results: Of 101 patients, 60 (58.4%) underwent operative management. A significant difference in 90-day mortality between operative and nonoperative groups was observed (15.0 vs. 34.1%; P =0.031). Operative management tends to yield similar therapeutic benefits in timely [odds ratio (OR), 0.250; 95% confidence interval (CI), 0.05–1.14; P =0.073) and delayed (OR, 0.42; 95% CI, 0.12–1.47; P =0.175) treatment groups. Based on perforation severity score stratification, operative management significantly decreased the risk of 90-day mortality (OR, 0.211; 95% CI, 0.064–0.701; P =0.011) for patients in low-risk and moderate-risk groups but may be detrimental for patients in high-risk group (OR, 1.333; 95% CI, 0.233–7.626; P =0.746). Conclusions: Operative management might be superior to nonoperative management for low-risk and moderate-risk patients with spontaneous rupture of the esophagus. However, for patients at high risk, operative management might not provide additional benefits compared with nonoperative management. Further research involving larger sample sizes is required for accurate patient stratification and conclusive evidence-based guidelines.

21 April 2025 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
XZXiaojiang Zhou
Xiaojiang Zhou
LYLin Yang
Lin Yang
JDJingjing Deng
Jingjing Deng
WGWankai Guo
Wankai Guo
DLDi Liu
Di Liu
CXChuan Xu
Chuan Xu
The accurate prognostication and recurrence monitoring of esophageal cancer (EC) are pivotal yet challenging. Despite the promising roles of squamous cell carcinoma antigen (SCC) and cytokeratin 19 fragment (CK19 Fragment) as cancer biomarkers in EC, their prognostic value remains unquantified. This meta-analysis is the first to quantitatively assess the relationship between serum levels of SCC and CK19 Fragment and EC prognosis, aiming to bridge this knowledge gap. We conducted a comprehensive and systematic literature search across PubMed, Web of Science, Cochrane Library, and Embase databases, and Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and other survival outcomes were extracted and analyzed using random-effects or fixed-effects models depending on heterogeneity among the studies. 7309 patients from 29 studies were finally included in this meta-analysis. The quantitively summarized data revealed that elevated level of SCC and CK19 Fragment in serum was significantly correlated to poorer prognosis of EC patients with the pooled HR of OS was 1.25 (95%CI: 1.04–1.50, P < 0.05) and 1.69 (95%CI: 1.25–1.27, P < 0.05), respectively. Subgroup analyses indicated that the prognostic value of these biomarkers varied across different patient populations and treatment modalities. This meta-analysis demonstrated that SCC and CK19 Fragment levels in serum were both strong prognostic biomarkers of EC patients. The elevated level of SCC and CK19 Fragment in serum was significantly associated with worse survival outcomes, advocating for the integration of these biomarkers into prognostic assessments to improve decision-making processes in the management of EC. CRD42022311617.

4 January 2024 in International Journal of Surgery
Verified
Journal Article
Open access
YLYixin Liu
Yixin Liu
JZJianfeng Zhou
Jianfeng Zhou
YGYimin Gu
Yimin Gu
WHWeipeng Hu
Weipeng Hu
HLHaonan Lin
Haonan Lin
LCLong-Qi Chen
Long-Qi Chen
Background: Reports on combined resection for synchronous lung lesions and esophageal cancer (CRLE) cases are rare and mostly individual cases. Furthermore, the feasibility of CRLE has always been a controversial topic. In the current study, the authors retrospectively analyzed the feasibility of CRLE and established an individualized prediction model for esophageal anastomotic leaks after CRLE by performing a multicenter retrospective study. Methods: Patients who underwent esophagectomy between January 2009 and June 2021 were extracted from a four-center prospectively maintained database, and those with CRLE at the same setting were matched in a 1:2 propensity score-matched (PSM) ratio to esophagectomy alone (EA) patients. A nomogram was then established based on the variables involved in multivariate logistic regression analysis. Internal validation of the nomogram was conducted utilizing Bootstrap resampling. Decision and clinical impact curve analysis were computed to assess the practical clinical utility of the nomogram. A prognosis analysis for CRLE and EA patients by Kaplan–Meier curves was conducted. Results: Of the 7152 esophagectomies, 216 cases of CRLE were eligible, and 1:2 ratio propensity score-matched EA patients were matched. The incidence of anastomotic leaks following CRLE increased significantly (P=0.035). The results of the multivariate analysis indicated the leaks varied according to the type of lung resection (anatomic>wedge resection, P=0.016) and site of resected lobe (upper>middle/low lobe; P=0.027), and a nomogram was established to predict the occurrence of leaks accurately (area under the curve=0.786). Although no statistically significant difference in overall survival (OS) was observed in the CRLE group (P=0.070), a trend toward lower survival rates was noted. Further analysis revealed that combined upper lobe anatomic resection was significantly associated with reduced OS (P=0.027). Conclusion: Our study confirms that CRLE is feasible but comes with a significantly increased risk of anastomotic leaks and a concerning trend of reduced survival, particularly when upper lobe anatomic resections are performed. These findings highlight the need for careful patient selection and surgical planning when considering CRLE.

8 January 2026 in Frontiers in Surgery
Verified
Journal Article
Open access
PDF file
DKDemiao Kong
Demiao Kong
JDJingjing Deng
Jingjing Deng
QMQikun Mao
Qikun Mao
XZXun Zhao
Xun Zhao
LYLimin Ye
Limin Ye
LYLin Yang
Lin Yang
Background: Three-dimensional (3D) printing and bioprinting technologies have rapidly evolved into essential tools in thoracic surgery, enabling personalized anatomical modeling, implant fabrication, and tissue engineering. However, the global research landscape and thematic evolution of this field remain incompletely characterized. Methods: A comprehensive bibliometric and visualized analysis was conducted using the Web of Science Core Collection, Scopus, and PubMed databases, covering studies published between 2008 and 2024. Data visualization and network analyses were performed using CiteSpace (v6.2.4R) and VOSviewer (v1.6.18) to assess publication trends, author and institutional collaborations, co-citation patterns, and keyword evolution. Results: A total of 740 publications were identified, including 627 original articles and 113 reviews, contributed by 4,077 authors from 1,277 institutions across 71 countries. Annual publications increased steadily, peaking in 2024. China ranked first in publication volume (205 papers, 27.7%), while the United States had the highest citation impact (10,969 citations; 58.66 citations per paper). The most active journals were Journal of Thoracic Disease and Medical Physics. Keyword and co-citation analyses revealed three main research phases (1): anatomical modeling and surgical simulation (2008–2015) (2); prosthetic design and clinical application (2016–2020); and (3) tissue engineering, radiotherapy guidance, and bioprinting innovations (2021–2024). Emerging hotspots included electrospinning, volatile organic compound sensing, and tumor-specific implant customization. Conclusion: Global research on 3D printing in thoracic surgery has expanded rapidly, with a clear transition from mechanical reconstruction toward biologically functional and regenerative approaches. The integration of bioprinting with advanced imaging, artificial intelligence, and robotics holds promise for personalized, precision thoracic surgery. Continued interdisciplinary collaboration will be essential to accelerate clinical translation and regulatory approval of biofabricated constructs.